Navigation Links
Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
Date:10/6/2011

tuzumab (Herceptin®).  Only 25% of breast cancer patients have HER-2 levels high enough to be eligible for Herceptin.

A controlled, randomized, and single-blinded Phase II clinical study of AE37 in HER-2 expressing breast cancer patients is currently underway to establish clinical efficacy.  The study endpoint is a reduction in cancer relapse after two years compared to patients not receiving AE37.  There are currently over 200 patients enrolled in the study with either node positive or high-risk node-negative breast cancer.  While positive preliminary results suggested that statistically definitive results could be obtained in 2012, the company opted to enroll an additional 100 patients in early 2011 to ensure sufficient patient numbers.  In particular, these additional patients are required to have low HER-2 expression levels such that they are not eligible for trastuzumab.  It is anticipated that a planned Phase 3 trial will be conducted in this specific patient population.

The many clinical trials conducted in the field of active immunotherapy of cancer over the last decade have provided increasing evidence that it is possible to engage the immune system to focus on and destroy cancer cells. Part of what has been learned over this time is the importance of specific activation of CD4+ T-helper cells in the generation of a robust and effective immune response. Equally clear is the validity of the HER2 protein as a target for cancer therapy. Importantly, HER2 is expressed at low to intermediate levels in a high percentage of breast as well as many other tumor types.  HER2 expression at these levels requires active immunotherapy, such as AE37, rather than passive immunotherapy such as Herceptin. For this reason, the company is continuing with plans for a Phase II prostate cancer study as well as other novel clinical applications of AE37 with interested parties.

"Antigen Express continues to make progress
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Antigen Express AE37 Cancer Vaccine Featured in Scientific American
2. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
3. Generex Provides Update on Spinout of Antigen Express
4. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
5. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
6. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
7. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
8. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
9. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
10. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
11. Medicago succesfully expresses VLP antigen for A H1N1 strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DALLAS , Sept. 18, 2014 /PRNewswire-iReach/ -- ... and China Acetic Acid Industry" and "2014 Deep ... Industry" reports to its research database. ... 2014 Deep Research Report on Global and China ... research report on China ...
(Date:9/18/2014)... 18, 2014 On Tuesday, Secretary of ... Jim Risch for National Lab Day on the Hill. ... the national laboratory system. Durbin and Risch also formally ... increase awareness of the reach of the national labs ... to address some of our nation's most pressing challenges. ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... a FM-4910 listed material, to stay competitive in ... These high-performance materials ultimately impact product quality ... President and owner. , Established in 1980 in ... strong as many fabricators have left the business. ...
(Date:9/18/2014)... septembre 2014 Mapi, société créée à ... a été depuis 40 ans l,un des ... traditionnelles par des évaluations recentrées sur le ... impacts économiques des traitements. Logo ... A cours d,une récente conférence téléphonique avec ...
Breaking Biology Technology:Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 21974 - 2014 - Mapi fête ses 40 ans 2
... BioMS Medical Corp (TSX: MS), a leading developer in the treatment of ... will present at BioFinance 2009 in Toronto., WHEN: ... Marriott Eaton Centre Hotel (Trinity V room), ... Toronto, ON, About ...
... 24 United Therapeutics Corporation (Nasdaq: UTHR ... first quarter financial results before market open on Friday, ... on Friday, May 1, 2009, at 9:00 a.m. Eastern ... with international callers dialing 719-325-4795. A rebroadcast of ...
... 24 LyondellBasell Industries today announced that LyondellBasell ... Lyondell Chemical Company,s reorganization filing under Chapter 11 ... European holding company against claims by certain financial ... S.C.A. is a holding company incorporated in Luxembourg. ...
Cached Biology Technology:BioMS Medical to present at BioFinance 2009 2LyondellBasell Adds Holding Company to Chapter 11 Protection 2
(Date:9/18/2014)... the International Space Station ever starts a "frequent flyers" ... status. Recently the orbiting laboratory has hosted increasing numbers ... returned from the space station in April, and another ... third experiment is planned to launch in December. , ... around the world-- and in space. Model organisms can ...
(Date:9/18/2014)... of Americans to undertake jaunts into the countryside each year ... within a century, according to new research. , Climate change ... United States as summer temperatures linger later into the year, ... and Biogeography . For instance, the paper birch a ... Hampshire could change color one to three weeks later ...
(Date:9/18/2014)... stored in DNA, tiny strands of nucleic acid that ... express this genetic data, our DNA is copied into ... that perform tasks in our cells. , Several ... molecule. Unlike all other known RNAs, this molecule is ... are abundant, little has been known about how they ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... , April 27 Southwest Bancorp, Inc. (Nasdaq: OKSB ), ... shares of common stock at a price to the public of $12.50 ... offering was increased from the previously announced offering size of approximately $40 ... . , , , ...
... China , April 27 /PRNewswire-Asia-FirstCall/ ... or "the Company"), the,Xianyang-based manufacturer of a leading ... ("Xin Aoxing"), and other pharmaceutical,products, announced today it ... and Drug Administration ("SFDA") for marketing Xin Aoxing,Oleanolic ...
... Katie Michaels , star of Barely Legal 100 and other fine ... returning to Phoenix to attend game seven of the NHL playoffs between ... , , ... , "After finishing ...
Cached Biology News:Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 2Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 3Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule 2Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule 3Adult Star Katie Michaels Attending NHL Game 7 Red Wings vs. Coyotes 2
... 20-HETE is a cytochrome P450 (CYP450) metabolite ... the renal and cerebral vasculature. In rat ... mediates pressure-induced autoregulatory vasoconstriction. 20-HETE is excreted ... of free 20-HETE (20-40 pg/ml in human ...
... designed to rapidly and reliably amplify unknown ... Technology. APAgene provides hassle-free, ready-to use components, ... ingredients are provided in each kit. The ... gap filling, localized cloning of genomic DNA, ...
Mol wt: average mol wt16,951.27 Da by calculation...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
Biology Products: